WO2009115429A1

WO2009115429A1 - Food preparation and pharmaceutical composition containing an embryonic extract

Info

Publication number: WO2009115429A1
Application number: PCT/EP2009/052764
Authority: WO
Inventors: Joan Cunill Aixela
Original assignee: Individual
Current assignee: Individual
Priority date: 2008-03-19
Filing date: 2009-03-10
Publication date: 2009-09-24
Anticipated expiration: 2010-09-19
Also published as: ES2337537A1; ES2337537B2; ES2337537B8

Abstract

The invention relates to a food preparation and pharmaceutical composition containing an embryonic extract and their respective uses. The food preparation comprises an embryonic germ in the final gastrula phase extracted from a fertilized and incubated egg. In addition, the pharmaceutical composition contains as an active substance an embryonic extract in the final gastrula embryonic development stage extracted from a fertilized and incubated egg. Said preparation is used as a food supplement for the prevention of hair loss. In addition, said pharmaceutical composition can be used as a medicament for antidegenerative treatments.

Description

D E S C R I P T I O N

FOOD PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING AN EMBRYONIC

EXTRACT

5

Technical Field of the Invention

Food preparation and pharmaceutical composition containing an embryonic extract and their respective uses. 0 Background of the Invention

It is known that during the cell organogenesis period, certain regulatory substances prevent the unlimited cell multiplication typical of the development of certain diseases, such as cancer.

This fact has caused certain experiments to be carried out to determine 5 the effects of homogenized embryonic tissues on the growth and dissemination of tumours.

Following this line of research, preparations intended for the prevention and treatment of cancer the active ingredient of which are embryonic extracts taken in specific embryonic development stages have been disclosed. 0 By way of example, documents CA 2197050 and WO 981 1905 stand out, describing respective preparations containing fertilized hen egg extracts, which have preferably been incubated from between approximately 8 and approximately 10 days, and embryonic trout egg extracts, in a development stage of 5 to 20 somites. 5

Disclosure of the Invention

The applicant has been able to verify that the administration of embryo extracts taken in a stage before the extraction stages used up until now, and very specific of embryonic development, has surprisingly revitalizing effects that are0 most likely related to a significant effect on the cell division rate.

To that end, the embryonic germ must be obtained before the formation of segmented mesodermal tissue masses, or somites, in the embryonic development, but once the blastula phase has been completed. Specifically, the embryonic germ is obtained in the food preparation of the invention when the three embryonic ectoblast-mesoblast-entoblast layers have been developed in a fertilized and incubated egg for a specific period, whereby the food preparation comprises at least one embryonic germ in the final gastrula phase.

According to another feature of the preparation according to the invention, the embryonic germ is extracted from a hen egg during the period comprised between 18 and 30 hours after its incubation.

According to a variant for obtaining it, the preparation further comprises part of the yolk of the egg sucked during the extraction of the germ by suction.

The preparation is preferably frozen for its conservation and subsequent oral administration.

The administration of the preparation in humans is indicated as a regenerating agent in the event of skin dryness or hair loss.

The administration of the preparation in animals is indicated as a revitalizing agent and stimulant of the defences in the event of suffering from infectious or parasitic diseases such as Leishmaniasis in dogs or viral immunodeficiencies in cats.

According to another aspect of the invention, a pharmaceutical composition containing as an active substance at least one embryonic extract in the final gastrula embryonic development stage extracted from a fertilized and incubated egg is disclosed.

The composition is intended for its use in antidegenerative treatments, for treating arthrosis, cirrhosis, nephritis or neurodegenerative processes.

The composition is also intended for its use in regenerative treatments in mammals. According to another application, the composition is intended for its use as a coadjuvant of treatments against cancer, such as radiotherapy and chemotherapy.

Detailed Description of the Invention An example for obtaining at least one embryonic germ for the food preparation according to the invention is described below.

A fertilized hen egg is removed from an incubator after a period comprised between 18 and 36 hours after its incubation. An embryonic germ in the final gastrula phase, before the formation of somites, is thus achieved. The content obtained after the breaking of the shell, formed by the yolk and the white, is subsequently deposited on a sterile tray.

Then, the yolk is shaken by rocking the tray until the embryonic germ is located in a dorsal and centred position. In said position, the suction of said embryonic germ is then carried out, which germ is contained together with the surrounding yolk in an amount of volume approximately between 0.5 and 2 ml, according to the suction carried out. A sterile syringe, plunger or pipette is used for the mentioned suction, in a way which is known in itself.

Before its administration, it is frozen for its storage and it has to be thawed at the time of its use. Even so, it can be administered directly without the freezing process.

Alternatively, it can be carried out the suction of the embryonic germ that is contained together with the surrounding yolk in a greater amount of volume, approximately 5 ml. After said explanation for obtaining said preparation several practical examples with different users will be explained, first two cases in animals and then another two cases in human patients are explained.

In a male European feline patient aged 16 years and weighing 4 Kg which was suffering from anorexia, cachexia, chronic nephritis and generalized pain, a treatment based on the preparation according to the invention was started. A daily dose of 1 ml of extract was administered. After two weeks, the patient recovered its appetite, the pain disappearing and all the vital signs being normalized and putting on weight up to the current 5.5 kg three years after the start of the treatment. In this case, the life expectancy of said patient greatly exceeds the average by more than 20%.

In another patient, in this case a male boxer dog aged 9 years which was affected with Leishmaniasis and malignant tumours, in addition to subjecting the patient to an operation and to a treatment for Leishmaniasis with the relevant medication, a dose of egg extract according to the invention was applied to it at the rate of 2 ml twice a day. Today, after three years, it has not presented recurrences of the tumours and has got over the Leishmaniasis, its quality of life being optimal.

In a human patient, a male aged 41 years who was affected with baldness, prostatitis, tiredness, cholesterolemia, tachycardia and high blood - A -

pressure, a treatment based on the preparation according to the invention was started. A dose of 2 ml was administered three times a day, follicle growth, normalization of prostatic symptoms, normalization of the cardiac rhythm and the blood pressure starting to be observed six months after the start of the treatment. After 5 years it can be verified that the quality of life of said patient has been improved.

In another human patient, in this case a woman aged 39 years affected with cancer with several metastases for nine years, in treatment with chemotherapy and radiotherapy, the treatment was started to be administered at the rate of 2 ml with nine daily doses. Said treatment has been applied in said patient for five months and a substantial improvement in the quality of life, the resistance to tiredness increasing, increase in the vitality and physical capacity have been observed.

After these described examples, a global sample has been made to study the results. In said study sample comprising animals, 15 dogs and 2 cats, and eight humans, it has been possible to conclude that harmful or side effects do not occur. Specifically, the results obtained are set forth below.

At the animal level:

In three of the dogs of the sample, affected with Leishmaniasis, an increase in the regenerative capacity in bone marrow, red and white blood cells is observed clinically and analytically. In general, the quality of life is improved, whereby a dog having nephritis is cured and gets over kidney failure.

In another three dogs of the sample, affected with hepatitis, it is observed that they get over the disease without leaving sequelae. In another of the dogs, affected with hypothyroidism, with the administration of said egg extract, it allows it to reduce the thyroxine dose to half as the gland is activated.

In five of the dogs, affected with arthrosis and a cachexia condition, their mood is improved as is their life expectancy, exceeding it by 20%. In three of the dogs of the sample, affected with cancer, their quality of life is improved without weight loss, their life expectancy increasing.

In a cat of those of the sample, affected with nephritis, the disease is stabilized and its life expectancy increases, exceeding it by 30%.

In the other cat of the sample, affected with encephalitis with daily epileptic seizures, after the treatment with the egg extract the seizures were reduced to values of only one seizure a month.

At the human level:

In one of the human patients of the sample, affected with tiredness, pain in limbs and progressive baldness, the disappearance of all the fatigue symptoms is observed after the treatment and a follicle growth occurs in the patient.

In another female patient aged 70 years, affected with allergy, gastric pain and hair loss, a disappearance of all the symptoms and an improvement of the general condition of the patient are observed. In another human patient, affected with lung cancer and metastasis with chemotherapy treatment, a general improvement causing a greater vitality of the individual is observed after the treatment.

In another patient, with a non-consolidated femur fracture which has caused muscle mass loss and resistance to movement, an improvement in the movement and an increase in muscle strength are observed.

In one patient, affected with an inflammation of the intestinal mucosa causing abdominal pain, it is observed that the symptoms improve with said treatment.

In another three patients aged above 60 years, with tiredness, it is observed that the tiredness symptoms improve and the vital tone increases.

It should be emphatically mentioned that no side effect has been detected with the administration of said preparation in this type of treatment, its innocuousness being demonstrated in more than two hundred patients.

Claims

C L A I M S

1 .- A food preparation comprising at least one embryonic germ in the final gastrula phase extracted from a fertilized and incubated egg.

2.- The preparation according to claim 1 , characterized in that the embryonic germ is extracted from a hen egg during the period comprised between 18 and 30 hours after its incubation.

3.- The preparation according to claims 1 or 2, characterized in that it further comprises part of the yolk of the egg, which is sucked during the extraction of the germ by suction.

4.- The preparation according to any one of the previous claims, characterized in that it is frozen for its conservation and subsequent oral administration.

5.- The freeze-dried preparation according to any one of the previous claims.

6.- A use of a preparation according to any one of claims 1 to 5, for the preparation of a food supplement for the prevention of skin dryness.

7.- A use of a preparation according to any one of claims 1 to 5, for the preparation of a food supplement for the prevention of hair loss.

8.- A use of a preparation according to any one of claims 1 to 5, for the preparation of a stimulant of the defences indicated to combat infectious or parasitic diseases in dogs and cats.

9.- A use of a preparation according to any one of claims 1 to 5, for the preparation of a hair follicle regenerating agent.

10.- A pharmaceutical composition containing as an active substance at least one embryonic extract in the final gastrula embryonic development stage extracted from a fertilized and incubated egg.

1 1 .- A use of a composition according to claim 10 for the preparation of a medicament for antidegenerative treatments.

12.- A use of a composition according to claim 10 for the preparation of a medicament for regenerative treatments in mammals.

13.- A use of a composition according to claim 10 for the preparation of an anti-inflammatory medicament.

14.- A use of a composition according to claim 10 for obtaining a food supplement for its use as a coadjuvant of treatments against cancer, such as radiotherapy and chemotherapy.